7,544 Shares in Zoetis Inc. $ZTS Purchased by Hikari Tsushin Inc.

Hikari Tsushin Inc. purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 7,544 shares of the company’s stock, valued at approximately $1,176,000.

Several other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the last quarter. Obermeyer Wealth Partners lifted its position in shares of Zoetis by 11.3% during the first quarter. Obermeyer Wealth Partners now owns 1,932 shares of the company’s stock worth $318,000 after purchasing an additional 196 shares during the last quarter. PFG Advisors boosted its stake in shares of Zoetis by 28.9% during the first quarter. PFG Advisors now owns 9,627 shares of the company’s stock valued at $1,585,000 after purchasing an additional 2,157 shares during the period. KLP Kapitalforvaltning AS grew its holdings in shares of Zoetis by 41.1% in the first quarter. KLP Kapitalforvaltning AS now owns 216,874 shares of the company’s stock worth $35,708,000 after purchasing an additional 63,200 shares during the last quarter. Finally, Gratus Wealth Advisors LLC purchased a new position in Zoetis in the 1st quarter worth about $603,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $116.96 on Thursday. Zoetis Inc. has a one year low of $115.25 and a one year high of $181.85. The firm has a market cap of $51.54 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a 50-day simple moving average of $138.98 and a two-hundred day simple moving average of $150.66.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analysts Set New Price Targets

ZTS has been the subject of several research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Morgan Stanley dropped their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.